Thermo Fisher Scientific

Molecular testing content for clinical lab professionals and clinicians

  • Categories
    • Science and education
    • Product news
    • Case studies
    • Perspectives
    • Events
    • News

FDA grants emergency use authorization for new COVID-19, Flu A, Flu B, Combo Kit… just in time for the return of the flu

Clinical Conversation blog - home icon Product news 2 mins. Sharing ▼ Details ▼
  • Linked In sharing icon
  • Facebook sharing icon
  • Twitter sharing icon
  • Email sharing icon
15 Jul 2021 || By Peter Friebe Shares: 0 Versions of this article Original article. Tags Clinical testing, COVID-19, Influenza, RSV, Sars-cov-2

The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the SARS-CoV-2, influenza A and influenza B viruses in nasopharyngeal and nasal swabs. To help meet the demand for respiratory testing during the overlap of covid-19 and the flu season, the TaqPath COVID-19, Flu A, Flu B Combo Kit is approved for emergency use and available for purchase.

With the overlap of flu season and the novel coronavirus pandemic, it is vital that clinical and public health labs have access to a single test that can simultaneously detect RNA from multiple respiratory viruses. The TaqPath COVID-19, Flu A, Flu B Combo Kit can help labs expand their existing COVID-19 testing menu for respiratory samples while supporting low operational costs and workflow simplicity. The combo kit includes Applied Biosystems Pathogen Interpretive Software to automatically convert genetic analysis data into a readable report, helping reduce risk of user interpretation error.

“We knew that this season’s surge in COVID-19 infections could coincide with cases of influenza and RSV, so we worked quickly to develop a PCR-based diagnostic kit for detecting and differentiating these illnesses simultaneously,” said Mark Smedley, President of Genetic Sciences for Thermo Fisher. “Our kit provides laboratories with the ability to diagnose and monitor the spread of COVID-19 and similar illnesses, which may require different patient management, including quarantining measures.”  We are striving to supply the tests you need to meet respiratory testing demand during flu season.

The TaqPath COVID-19, Flu A, Flu B Combo Kit has not been FDA cleared or approved and is only authorized for the duration of the EUA.

Next Steps

  • Get information on workflow and performance of the TaqPath COVID-19, Flu A, Flu B Combo Kit summarized in a poster
  • Request a quote for the TaqPath COVID-19, Flu A, Flu B Combo Kit

Privacy StatementTerms & ConditionsLocationsSitemap

© 2025 Thermo Fisher Scientific. All Rights Reserved.

Home > Product news > FDA grants emergency use authorization for new COVID-19, Flu A, Flu B, Combo Kit… just in time for the return of the flu

Talk to us